Alessandro Spina

Brindisi, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Do quadruplet induction regimens for myeloma necessitate new mobilization strategies to obtain optimal CD34+ cell yields?

Do quadruplet induction regimens for myeloma necessitate new mobilization strategies to obtain optimal CD34+ cell yields?

Journal: Leukemia & lymphoma
Published: March 17, 2026

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 22, 2026

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Journal: Haematologica
Published: September 29, 2025

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology
Published: August 22, 2025

Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study.

Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study.

Journal: American journal of hematology
Published: March 17, 2025

Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey).

Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey).

Journal: Leukemia & lymphoma
Published: January 15, 2025

Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.

Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience.

Journal: Annals of hematology
Published: December 26, 2023

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

Journal: Leukemia & lymphoma
Published: July 07, 2023

Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.

Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia.

Journal: Leukemia research
Published: July 30, 2015

Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.

Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.

Journal: Leukemia & lymphoma
Published: July 09, 2013
Showing 1-10 of 10

Last Updated: 09/26/2026